195822-23-2
中文名称
N2,N3-双(4-氟苯基)喹喔啉-2,3-二胺
英文名称
LQZ-7I
CAS
195822-23-2
分子式
C20H14F2N4
分子量
348.35
MOL 文件
195822-23-2.mol
更新日期
2024/07/09 13:07:00
195822-23-2 结构式
基本信息
中文别名
化合物LQZ-7IN2,N3-双(4-氟苯基)喹喔啉-2,3-二胺
英文别名
LQZ-7IN2,N3-Bis(4-fluorophenyl)quinoxaline-2,3-diamine
2,3-Quinoxalinediamine, N2,N3-bis(4-fluorophenyl)-
所属类别
医药中间体：喹啉类化合物物理化学性质
熔点203 °C(Solv: ethanol (64-17-5))
沸点470.3±45.0 °C(Predicted)
密度1.390±0.06 g/cm3(Predicted)
储存条件Keep in dark place,Inert atmosphere,Room temperature
溶解度DMSO: 125 mg/mL (358.83 mM)
酸度系数(pKa)2.56±0.59(Predicted)
形态A solid
颜色Light yellow to green yellow
N2,N3-双(4-氟苯基)喹喔啉-2,3-二胺价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | HY-136538 | N2,N3-双(4-氟苯基)喹喔啉-2,3-二胺 LQZ-7I | 195822-23-2 | 5mg | 600元 |
| 2024/04/30 | HY-136538 | N2,N3-双(4-氟苯基)喹喔啉-2,3-二胺 LQZ-7I | 195822-23-2 | 10mM * 1mLin DMSO | 660元 |
| 2024/04/30 | HY-136538 | N2,N3-双(4-氟苯基)喹喔啉-2,3-二胺 LQZ-7I | 195822-23-2 | 10mg | 1000元 |
常见问题列表
生物活性
LQZ-7I 是一种靶向 survivin 的抑制剂。LQZ-7I 抑制生存素二聚化。LQZ-7I 口服有效抑制异种移植肿瘤生长并诱导肿瘤中生存素的损失。靶点
Survivin
体外研究
LQZ-7I has improved cytotoxicity with IC
50
s of 3.1 µM against C4-2 cells and 4.8 µM against PC-3 cells compared with the parent compound LQZ-7.
LQZ-7I (10 µM; 0-6 hours) treatment reduces the expression of survivin. However, LQZ-7I does not reduce the expression of XIAP, CIAP1, and CIAP2. LQZ-7I may be selective to its intended target survivin.
Western Blot Analysis
| Cell Line: | PC-3 or C4-2 cells |
| Concentration: | 10 µM |
| Incubation Time: | 0-6 hours |
| Result: | Reduced the expression of survivin. |
体内研究
LQZ-7I (100 mg/kg; oral gavage every other day for a total of ten treatments) significantly suppresses tumor growth without any notable adverse effect on the mice.
| Animal Model: | 6-week old male NSG mice |
| Dosage: | 100 mg/kg; 200 µL vehicle (90% corn oil/10% DMSO) |
| Administration: | Oral gavage every other day for a total of ten treatments |
| Result: | Significantly suppressed tumor growth without any notable adverse effect on the mice as indicated by lacking changes in body weight and in wet weight of major organs at the end of the study. |